People: Bristol-Myers Squibb Co (BMY)

Summary

Name	Age	Since	Current Position
James Cornelius	69	2010	Non-Executive Chairman of the Board
Lamberto Andreotti	62	2010	Chief Executive Officer, Director
Charles Bancroft	53	2011	Chief Financial Officer, Executive Vice President
Giovanni Caforio	48	2011	President, U.S. Pharmaceuticals
Louis Schmukler	57	2011	President - Global Manufacturing and Supply
Elliott Sigal	61	2011	Executive Vice President, Chief Scientific Officer, President - Research and Development, Director
Beatrice Cazala	56	2011	Executive Vice President - Commercial Operations
Paul von Autenried	51	2012	Senior Vice President - Enterprise Services, Chief Information Officer
Joseph Caldarella	57	2010	Senior Vice President, Corporate Controller
Ann Judge	47	2013	Senior Vice President - Human Resources
John Elicker	53	2012	Senior Vice President - Public Affairs and Investor Relations
Francis Cuss	58	2013	Executive Vice President, Chief Scientific Officer
Brian Daniels	53	2008	Senior Vice President - Global Development & Medical Affairs, Research and Development
Frances Heller	46	2012	Senior Vice President - Business Development
Samuel Moed	50	2012	Senior Vice President - Strategic Planning and Analysis
Sandra Leung	52	2007	General Counsel, Corporate Secretary
Lewis Campbell	65	2008	Lead Independent Director
Laurie Glimcher	61	1997	Independent Director
Michael Grobstein	70	2007	Independent Director
Alan Lacy	59	2008	Independent Director
Vicki Sato	64	2006	Independent Director
Gerald Storch	56	2012	Independent Director
Togo West	70	2008	Independent Director

» Insider Trading

Biographies

Name	Description
James Cornelius	Mr. James M. Cornelius is Non-Executive Chairman of the Board of Bristol-Myers Squibb Co. He served as the Chairman and Chief Executive Officer from February 2008 to May 2010 and served as the Chief Executive Officer from September 2006 to February 2008. From November 2005 through April 2006, Mr. Cornelius served as the Chairman of the Board and Chief Executive Officer (interim) of Guidant Corporation, a U.S. cardiac and vascular medical device company. He served as Guidant’s Non-Executive Chairman of the Board from 2000 until 2005. Mr. Cornelius is the Non-Executive Chairman of the Board of Directors of Mead Johnson Nutrition Company and a Director of Given Imaging Ltd. During the last 5 years, Mr. Cornelius was Vice Chairman of the Board of SpringBoard Medical Innovations, LLC and a Director of DirecTV Group.
Lamberto Andreotti	Mr. Lamberto Andreotti is Chief Executive Officer, Director of Bristol-Myers Squibb Co. Mr. Andreotti has been Chief Executive Officer since May 2010. He was President and Chief Operating Officer from March 2009 to May 2010. From March 2008 to March 2009, Mr. Andreotti served as Executive Vice President and Chief Operating Officer of BMS. From May 2007 until March 2008, he served as Executive Vice President of BMS and Chief Operating Officer of Worldwide Pharmaceuticals, a division of BMS. Mr. Andreotti served as Executive Vice President of BMS and President of Worldwide Pharmaceuticals from 2005-2007 and as Senior Vice President and International President of Worldwide Pharmaceuticals from 2002-2005. With his 14 years experience at BMS, both in the U.S. and internationally, and his prior experience at KABI Pharmacia and Pharmacia & Upjohn, Mr. Andreotti brings to Board knowledge of company and the biopharmaceutical industry. In his role as Chief Operating Officer, Mr. Andreotti gained insights into managing a global business in a complex and dynamic environment. During the last 5 years, Mr. Andreotti was Vice Chairman of the Board of Directors of Mead Johnson Nutrition Company.
Charles Bancroft	Mr. Charles A. Bancroft is Chief Financial Officer, Executive Vice President of Bristol-Myers Squibb Co. He has been appointed as Executive Vice President effective October 19, 2011. He joined Bristol-Myers Squibb in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received a B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.
Giovanni Caforio	Dr. Giovanni Caforio M.D., is President, U.S. Pharmaceuticals of Bristol-Myers Squibb Co. He was most recently senior vice president, Oncology and Immunology Global Commercialization. From 2007 to 2009 – Senior Vice President, U.S. Oncology, Worldwide Pharmaceuticals, a division of the Company, 2009 to 2010 – Senior Vice President, Oncology, Global Commercialization, 2011 to 2011 – Senior Vice President, Oncology and Immunoscience, Global Commercialization.
Louis Schmukler	Mr. Louis S. Schmukler is President - Global Manufacturing and Supply of Bristol-Myers Squibb Co. From 2007 to 2009 he was Senior Vice President, Pharmaceutical Operating Unit, Wyeth and from 2009 to 2011 – Senior Vice President, Specialty/Biotechnology Operating Unit, Pfizer.
Elliott Sigal	Dr. Elliot Sigal, M.D., Ph.D., has resigned as Executive Vice President, Chief Scientific Officer, President - Research and Development, Director of Bristol-Myers Squibb Co., effective June 30, 2013. He has been Chief Scientific Officer and President of Research and Development since October 2004 and an Executive Vice President since November 2006. Dr. Sigal joined BMS in November 1997 as Vice President of the newly created department of Applied Genomics and since then has held positions of increasing responsibility in both discovery and development. Dr. Sigal is a member of the President’s Council of The J. David Gladstone Institutes, a member of the Forum on Drug Discovery, Development and Translation of the Institute of Medicine and a member of the Biomedical Scientific Advisory Board of the Vanderbilt University Medical Cente. Prior to medical school Elliott studied engineering and management at Purdue University, where he received a Bachelor of Science and a Master of Science, and his Ph.D. Dr. Sigal is a Director of Mead Johnson Nutrition Company.
Beatrice Cazala	Ms. Beatrice J. Cazala is Executive Vice President - Commercial Operations of Bristol-Myers Squibb Co. She has been appointed as Executive Vice President effective October 19, 2011. From 2004 to 2008 – President, EMEA, Worldwide Medicines International, 2008 to 2009 – President, EMEA and Asia Pacific, Worldwide Medicines International, 2009 to 2010 – President, Global Commercialization, and President, Europe.
Paul von Autenried	Mr. Paul von Autenried is Senior Vice President - Enterprise Services, Chief Information Officer of Bristol-Myers Squibb Co. From 2007 to 2011 he was Vice President and Chief Information Officer, 2011 to 2012 – Senior Vice President and Chief Information Officer.
Joseph Caldarella	Mr. Joseph C. Caldarella is Senior Vice President, Corporate Controller of Bristol-Myers Squibb Co. He was 2005 to 2010, Vice President and Corporate Controller. He was 1998 to 2005 - Vice President, Finance, Pharmaceutical Research Institute, a division of the Company.
Ann Judge	Ms. Ann Powell Judge is Senior Vice President - Human Resources of Bristol-Myers Squibb Co. Prior to joining Bristol-Myers Squibb, Ms. Judge was chief human resources officer at Shire Pharmaceuticals. Before Shire, Ms. Judge was corporate vice president, Human Resources, for the Pharmaceutical Division at Wyeth. During her tenure at Wyeth, Ms. Judge also held positions of responsibility for human resources in the commercial organization and in the global manufacturing unit. Previously, she spent 13 years at The Dow Chemical Company, where she worked internationally in a variety of human resources positions of increasing scope and responsibility, spending some time living and working in Germany and Switzerland. Ms. Judge has a bachelor’s degree in Psychology from the University of Iowa and a master’s degree in Industrial Relations from the University of Minnesota.
John Elicker	Mr. John E. Elicker is Senior Vice President - Public Affairs and Investor Relations of Bristol-Myers Squibb Co. He served as 2000 to 2002 – Senior Director, Investor Relations, 2002 to 2010 –Vice President, Investor Relations, 2010 to 2012 – Senior Vice President, Investor Relations.
Francis Cuss	Dr. Francis M. Cuss, MB BChir, FRCP, has been appointed as Executive Vice President, Chief Scientific Officer of Bristol-Myers Squibb Co., effective July 1, 2013. Dr. Cuss joined Bristol-Myers Squibb in 2003 as senior vice president, Drug Discovery, adding responsibility for Discovery Medicine and Clinical Pharmacology in May 2006. Under Dr. Cuss' leadership, Bristol-Myers Squibb has consistently been rated a research organization based on cycle time, success rates and costs, having increased discovery output while maintaining a flat operating budget. Dr. Cuss and his team integrated Adnexus, Medarex and ZymoGenetics into the research organization, and have driven innovation in the research operating model, processes and governance. Dr. Cuss became a member of the company's Senior Management Team in 2010. Prior to joining Bristol-Myers Squibb, Dr. Cuss spent 14 years at Schering-Plough and three years at Glaxo, holding positions of increasing responsibility in discovery, clinical research and medical affairs in both the U.S. and Europe. Prior to joining the pharmaceutical industry, Dr. Cuss was a practicing physician and held several academic appointments, including as adjunct associate professor at Jefferson Medical College at Thomas Jefferson University in Philadelphia. Dr. Cuss received his medical training in the U.K. and holds medical degrees from Cambridge University. He is also a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine.
Brian Daniels	Dr. Brian Daniels M.D., is Senior Vice President - Global Development & Medical Affairs, Research and Development of Bristol-Myers Squibb Co. In this position, he helps drive the company’s focus on science and medicine as a central strategy of the company's next-generation BioPharma vision. Brian joined Bristol-Myers Squibb in 2000 as vice president of the Immunology, Pulmonary, and Dermatology therapeutic area, where he provided strategic oversight and led the early development of compounds including ORENCIA and belatacept. In 2002, Brian was promoted to vice president, Full Development, providing leadership to the development of six key clinical programs including REYATAZ and BARACLUDE. He also led efforts to improve productivity and to standardize and integrate the global execution of clinical trials as vice president of Global Development Operations. He was appointed senior vice president, Global Clinical Development in 2004, and to his current position in March 2008. Prior to joining Bristol-Myers Squibb, Brian spent four years at Merck Research Laboratories in clinical research, where he held the role of senior director, Pulmonary and Immunology. He has also worked in clinical research at Genentech. He holds bachelor’s and master’s degrees in biology from the Massachusetts Institute of Technology and a medical degree from Washington University School of Medicine. He received training in internal medicine at New York Hospital and in rheumatology at the University of California in San Francisco.
Frances Heller	Ms. Frances K. Heller, J.D. is Senior Vice President - Business Development of Bristol-Myers Squibb Co. Prior to joining Bristol-Myers Squibb, Ms. Heller was executive vice president, Business Development at Exelixis. Prior to that, Ms. Heller was head of Strategic Alliances at Novartis Pharmaceuticals where she was responsible for transactions with partners in the pharmaceutical and biotech industry as well as academic institutions worldwide. Previously, she was Corporate and Intellectual Property counsel for Celera Genomics. Ms. Heller serves on the board of directors of several biotech companies and universities, is a Trustee at the Dana Farber Cancer Institute and teaches a business class at Stanford University on the biotech and pharmaceutical industry. Ms. Heller is a member of the California State Bar, is licensed by the U.S. Patent and Trademark Office, and has a B.S. in biology from Tulane University, an M.A. in biology from American University, and a J.D. from Golden Gate University School of Law.
Samuel Moed	Mr. Samuel J. Moed is Senior Vice President - Strategic Planning and Analysis of Bristol-Myers Squibb Co. He served as 2005 to 2010 – Senior Vice President, Worldwide Strategy and Operations, 2010 to 2012 – Senior Vice President, Strategy.
Sandra Leung	Ms. Sandra Leung is General Counsel, Corporate Secretary of Bristol-Myers Squibb Co. She joined Bristol-Myers Squibb in 1992 as a staff attorney in the litigation department. In 1996 she became assistant counsel and one year later, was named associate counsel. In 1999, Sandy was appointed to the position of counsel and corporate secretary, and in 2002 became corporate vice president. Four years later, Sandy was named acting general counsel in addition to her other duties, and in 2007, she was named to her current position as senior vice president and general counsel. Before joining the company, Sandy spent eight years as a prosecutor in the Manhattan District Attorney’s office and was one of New York City’s first Asian-American female prosecutors. During her time there, she was part of the original special victims unit. She earned her law degree from Boston College of Law and her bachelor’s degree from Tufts University.
Lewis Campbell	Mr. Lewis B. Campbell is Lead Independent Director of Bristol-Myers Squibb Co. He has served as the Executive Chairman and Chief Executive Officer of Navistar International Corporation, manufacturer of commercial trucks, buses, RVs, defense vehicles and engines, since August 2012. Mr. Campbell served as Non-Executive Chairman of Textron Inc. from December 2009 to August 2010 and served as Chairman and Chief Executive Officer of Textron from February 1999 through November 2009 when he retired as Chief Executive Officer. Mr. Campbell is a member of The Business Council and a member of the Business Roundtable. Mr. Campbell is a demonstrated leader with keen business understanding. Mr. Campbell is on the Board of Directors of Sensata Technologies Holding N.V. and the Board of Trustees of Noblis, Inc. During the last 5 years, Mr. Campbell was the Chairman of the Board of Directors of Textron Inc.
Laurie Glimcher	Dr. Laurie H. Glimcher M.D., is Independent Director of Bristol-Myers Squibb Co. She has served as the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and the Cornell University Provost for Medical Affairs since January 2012. She had been the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School from 1990 to December 2011. She is a Fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences USA, and a member of the Institutes of Medicine of the National Academy of Sciences. She is also a member of, and a past President of, the American Association of Immunologists. She was elected to the American Society of Clinical Investigation, the American Association of Physicians and the American Association for the Advancement of Science. Dr. Glimcher serves on the Memorial Sloan-Kettering Cancer Center Board of Overseers and on the Scientific Advisory Boards of Health Care Ventures, Inc., Nodality Inc., Abpro, Inc., Theraclone Sciences, Inc. and American Asthma Foundation. Dr. Glimcher is a Director of Waters Corporation.
Michael Grobstein	Mr. Michael Grobstein is Independent Director of Bristol-Myers Squibb Co. He is a retired Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. Mr. Grobstein worked with Ernst & Young from 1964 to 1998, and was admitted as a partner in 1975. He served as a Vice Chairman-International Operations from 1993 to 1998, as Vice Chairman-Planning, Marketing and Industry Services from 1987 to 1993, and Vice Chairman-Accounting and Auditing Services from 1984 to 1987. He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy. He also serves on the Board of Directors of the Peer Health Exchange, Inc. Mr. Grobstein is a Director of Given Imaging Ltd.
Alan Lacy	Mr. Alan J. Lacy is Independent Director of Bristol-Myers Squibb Co. He has been a Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, since 2007. From 1994 to 2006, he was employed by Sears, Roebuck and Co., retail company, and following its acquisition, Sears Holdings Corporation, broadline retailer. Mr. Lacy held executive level positions of increasing responsibility in finance and operations, including his service as Chief Executive Officer and Chairman of the Board from 2000 to 2005. He also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. He is Trustee and former Chairman of the National Parks Conservation Association. Mr. Lacy is a Director of The Hillman Companies, Inc., Dave & Buster’s, Inc. and Earth Fare Inc. He is also a Trustee of Fidelity Funds. During the last 5 years, he was a Director of The Western Union Company.
Vicki Sato	Dr. Vicki L. Sato Ph.D., is Independent Director of Bristol-Myers Squibb Co. She has been a professor of management practice at the Harvard Business School and professor of the practice of molecular and cell biology at Harvard University since July 2005. In 2005, Dr. Sato retired as President of Vertex Pharmaceuticals Incorporated, a global biotechnology company, where she was responsible for research and development, business and corporate development, commercial operations, legal, and finance. Dr. Sato also served as Chief Scientific Officer, Senior Vice President of Research and Development, and Chair of the Scientific Advisory Board at Vertex before being named President in 2000. Dr. Sato is a Director of PerkinElmer Corporation and of Galapagos NV. During the last 5 years, she was a Director of Alnylam Pharmaceuticals, Inc. and Infinity Pharmaceuticals, Inc.
Gerald Storch	Mr. Gerald L. Storch is Independent Director of Bristol-Myers Squibb Co. He has been the Chairman and Chief Executive Officer of Toys“R”Us, Inc. since February 2006. He will be transitioning from his role as Chief Executive Officer of Toys“R”Us, but will continue to remain Chairman. Prior to joining Toys“R”Us, Inc., Mr. Storch served as Vice Chairman of Target Corporation. He joined Target in 1993 as Senior Vice President of Strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company. Mr. Storch is a member of the Committee Encouraging Corporate Philanthropy and is on the board of Toys“R”Us Children’s Fund.
Togo West	Honourable Togo Dennis West, Jr., is Independent Director of Bristol-Myers Squibb Co. He has been Chairman of TLI Leadership Group, a strategic consulting firm since 2006 and Chairman of Noblis, Inc., a nonprofit science and technology company since 2001. From 2004 to 2006, Secretary West was the Chief Executive Officer of the Joint Center for Political and Economic Studies, a nonprofit research and public policy institution. He served as Of Counsel to the Washington, D.C. based law firm of Covington & Burling from 2000 to 2004. Secretary West served as U.S. Secretary of Veterans Affairs from 1998 to 2000 and as U.S. Secretary of the Army from 1993 to 1997. He is Secretary West is a Director of FuelCell Energy, Inc. and Krispy Kreme Doughnuts, Inc. During the last 5 years, he was a Director of AbitibiBowater Inc.

Basic Compensation

Name	Fiscal Year Total
James Cornelius	10,859,000
Lamberto Andreotti	17,202,000
Charles Bancroft	8,567,310
Giovanni Caforio	--
Louis Schmukler	--
Elliott Sigal	8,343,680
Beatrice Cazala	8,031,020
Paul von Autenried	--
Joseph Caldarella	--
Ann Judge	--
John Elicker	--
Francis Cuss	--
Brian Daniels	--
Frances Heller	--
Samuel Moed	--
Sandra Leung	5,892,770
Lewis Campbell	--
Laurie Glimcher	--
Michael Grobstein	--
Alan Lacy	--
Vicki Sato	--
Gerald Storch	--
Togo West	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
James Cornelius	0	0
Lamberto Andreotti	700,526	1,338,240
Charles Bancroft	47,125	353,223
Giovanni Caforio	0	0
Louis Schmukler	0	0
Elliott Sigal	875,401	3,588,940
Beatrice Cazala	156,662	1,053,900
Paul von Autenried	0	0
Joseph Caldarella	0	0
Ann Judge	0	0
John Elicker	0	0
Francis Cuss	0	0
Brian Daniels	0	0
Frances Heller	0	0
Samuel Moed	0	0
Sandra Leung	0	0
Lewis Campbell	0	0
Laurie Glimcher	0	0
Michael Grobstein	0	0
Alan Lacy	0	0
Vicki Sato	0	0
Gerald Storch	0	0
Togo West	0	0

Insider Trading

Name	Shares Traded	Price
CAFORIO GIOVANNI	26,647	$46.29
CAZALA BEATRICE J	96,000	$46.99
DANIELS BRIAN	15,000	$39.93
CORNELIUS JAMES M	10,000	$39.78
CORNELIUS JAMES M	10,000	$39.91
ANDREOTTI LAMBERTO	12,754	$40.20
ANDREOTTI LAMBERTO	8,859	$0.00
ANDREOTTI LAMBERTO	13,989	$0.00
ELICKER JOHN E	679	$40.20
ELICKER JOHN E	1,508	$0.00
CORNELIUS JAMES M	10,000	$39.85
MOED SAMUEL J	5,000	$0.00
MOED SAMUEL J	2,269	$39.72
CORNELIUS JAMES M	10,000	$39.66
SIGAL ELLIOTT	919	$39.65
SIGAL ELLIOTT	175,143	$39.61
SIGAL ELLIOTT	90,234	$39.61
SIGAL ELLIOTT	459	$39.65
SIGAL ELLIOTT	88,132	$39.63
SIGAL ELLIOTT	202,405	$24.74
SIGAL ELLIOTT	103,500	$25.45
SIGAL ELLIOTT	919	$39.65
SIGAL ELLIOTT	25,795	$22.73
SIGAL ELLIOTT	11,092	$24.74
SIGAL ELLIOTT	9,600	$40.00

» Full list on Insider Trading

People: Bristol-Myers Squibb Co (BMY)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: